Cardiology

James L. Januzzi, MD, provides insight on the pathophysiology of obstructive hypertrophic cardiomyopathy (oHCM) and comments on small-molecule myosin inhibitors as an emerging therapeutic option.

Ahmad Masri, MD, MS, provides an update on the the development of the cardiac myosin inhibitor class and offers perspective on what the future might hold for the class beyond cardiomyopathy.

Tom Nguyen, MD, discusses a recent study he led comparing outcomes of TAVR explantation based on transcatheter heart valve type.

Older adults who use a salt substitute had a 40% lower incidence of experiencing hypertension than people who use regular salt.

FDA advisory committee votes 13-1 that the benefits outweigh the risk of use for Abbott's TriClip for tricuspid regurgitation, pending FDA decision expected in 2024.

Michelle Kittleson, MD, PhD, provides insight into the potential impact of a new risk score for heart transplant allocation as well as the need for more equitable cardiovascular care in the US.

A novel risk score developed by University of Chicago investigators outperformed conventional models in predicting death in heart transplant candidates, which could help bring the field closer to optimal and equitable allocation.

A recent survey indicates many US adults are unaware of their vital health metrics, highlighting the need for increased education on heart disease prevention.

Anticoagulation and antiplatelet therapy show no significant difference in recurrent stroke risk among patients with cryptogenic stroke and evidence of atrial cardiopathy.

Deepak Bhatt, MD, MPH, discusses the need to improve in-hospital initiation and uptitration of guideline-directed medical therapy in heart failure.

A new study found balance and falling were linked to an increased risk of all-cause mortality, as well as cause-specific mortality from cardiovascular disease and diabetes.

Blood thinners added to clot-busting medication did not improve 90-day stroke outcomes, leading to early discontinuation of the MOST trial.

This recap of top cardiology news from January 2024 spotlights pipeline updates, new guidance on peripheral interventions, and a celebration of what may be the single most impactful public health address in the history of the United States.

Findings highlight the potential benefits of implementing home-based screening for albuminuria in the general population to reduce the burden of kidney and cardiovascular diseases while maintaining cost-effectiveness.

The FDA's acceptance of the NDA for acoramidis in ATTR-CM was announced on February 05, 2024 and assigns a November 2024 PDUFA for the agent.

Alirocumab every 2 or 4 weeks significantly reduced LDL-C in pediatric patients with inadequately controlled heterozygous familial hypercholesterolemia.

Tirzepatide, a dual GLP-1/GIP agonist approved for diabetes and obesity, was associated with significant blood pressure reductions in an analysis of the SURMOUNT-1 trial.

Although a new study found antidepressants from SSRI or SNRI did not increase the risk of hemorrhagic stroke or other serious bleeding in ischemic stroke survivors, the risk increased when taking antidepressants of other classes and anti-platelet medications.

The FDA approval of Edwards Lifesciences EVOQUE tricuspid valve replacement system for treatment of symptomatic severe tricuspid regurgitation is the first of its kind for a transcatheter therapy.

Study presented at ISC 2024 suggests Black women with hypertension before age 35 face a 3-fold increase in risk of stroke while hypertension before 45 linked to doubling in stroke risk.

Even when cholesterol levels were only moderately elevated, familial hypercholesterolemia variants were associated with greater cardiovascular risk.

This endocrinology month in review spotlights FDA news, a pair of studies examining cardiovascular and renal risk reduction in type 2 diabetes, results from a subtrial examining testosterone’s effect on fracture risk, and 4 new episodes of diabetes dialgoue

A recent analysis found risk factors linked to an embolism after VTE included Black race, interstitial fibrosis, advanced-stage disease, and increased operative duration.

In this feature, we acknowledge the impact of the 1964 Surgeon General report, its subsequent effect on public health, and present-day hurdles to optimized public health efforts through the eyes of our editorial advisory board members and other leading experts.

Across two large, diverse cohorts, TET2 CHIP was associated with a more than 2-fold higher risk of incident HF with preserved ejection fraction.

A recent statewide analysis in California found TAVR rates exceed SAVR for severe aortic stenosis, despite contradicting consensus guideline recommendations.

This cardiology case report from Brady Pregerson, MD, features a woman in her 50s presenting with 3 days of body swelling and dyspnea. Check out the EKG and see if you can determine the correct diagnosis!

A real-world analysis in the United States suggests hospital volume may not be the lone predictor of outcomes in pediatric cardiac surgery.

In recognition of 60 years since the historic contribution to modern understanding of the harmful effects of cigarette smoking, Albert Rizzo, MD, meets with the preventive cardiology expert to discuss the myriad of cascading effects delivered by the 1964 report.

In a 10-year follow-up study with over 1 million patients, multi-arterial grafting demonstrated superior long-term survival compared to single arterial grafting.